Pets will be exposed to other disease sources as more people adopt pets and bring them into their homes. Diseases are more likely to infect pets who contact with other animals, spend time outside, or travel. Urban areas can be favorable for the spread of some diseases. There has been an upsurge in pet border crossings, which increases the risk of diseases spreading to other areas. Pets can unintentionally help the spread of diseases that were previously unknown in some regions when traveling internationally.
For instance,
- In 2021, according to news reports from Hindustan Times, the parvovirus was infecting almost 2000 canines in Amravati (India)
- In 2022, according to Statista Research and Development, there are about 72.2 million pigs and 91.9 million cattle in the U.S., thus, there is still a chance that zoonotic illnesses could spread to people
- The World Organisation for Animal Health claims The H5N1 high pathogenicity avian influenza outbreaks in domestic poultry and wild birds were reported to WOAH in 67 countries across five continents in 2022, with over 131 million domestic chickens lost as a result of mortality or culling in afflicted farms and communities. Outbreaks were reported in 14 additional countries in 2023, as the disease continues to spread mostly in the Americas
Therefore, the growing incidences of pet diseases in the region are expected to drive market growth.
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/global-veterinary-pain-management-market
Data Bridge Market Research analyzes that the Global Veterinary Pain Management Market is expected to grow with a CAGR of 5.6% in the forecast period of 2023 to 2030 and is expected to reach USD 3,287,278.56 thousand by 2030. The analgesics segment is projected to propel the market growth due to rising pet diseases.
Key Findings of the Study
Rising R&D Activities and Product Approval for Veterinary Pain Management
Understanding animal pain better, enhancing the effectiveness and safety of pain management strategies, and broadening the spectrum of accessible treatments are all made possible by research. New pain-management medications, therapies, and technologies are always being discovered because of ongoing research. These discoveries can be used by pharmaceutical companies to create new, better ways to treat animal discomfort. This invention not only satisfies the changing demands of veterinarians but also draws in pet lovers looking for innovative therapies for their cherished animals.
Numerous pieces of research-based evidence back up the usage of particular pain management strategies in veterinary medicine. This evidence-based procedure inspires trust in both pet owners and veterinarians, encouraging greater use of efficient pain management methods. Animals have unique variances in how they perceive pain and react to therapy, according to research. This makes it possible for veterinarians to customize pain management programs to each animal's particular requirements, resulting in more efficient and individualized care.
Thus, the market is growing as a result of the growing research activities in veterinary pain treatment, which promote innovation, evidence-based practice, and education. This benefits animals by ensuring that they receive better, more compassionate pain management treatment, and it also creates new potential for veterinary pain management businesses and organizations, which is expected to create opportunities for market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customisable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Analgesics, Corticosteroids, and Alpha 2 Agonists), Drug Type (Branded and Generic), Mode of Purchase (Prescription Based and OTC), Animal Type (Companion animal and Production animal), Pain Source (Chronic Pain, Acute Pain, Post-Operative Pain, and Dental Pain), Dosage (Solid, Liquid, and Semi-Solid), Route of Administration (Parenteral, Oral, and Topical), End User (Veterinary Hospitals, Veterinary Clinics, Pet Shops, Animal Farms, Academic & Research Institutes, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Poland, Denmark, Sweden, Norway, Funland, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Taiwan, Vietnam, rest of Asia-Pacific, South Africa, Saudi Arabi, U.A.E., Egypt, Israel, Kuwait, Oman, Qatar, Bahrain, rest of the Middle East and Africa, Brazil, Argentina, and rest of South America
|
|
Market Players Covered
|
Zoetis Services LLC (U.S.), Elanco or its affiliates. (U.S.), Merck & Co., Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Vetoquinol (France), Virbac (U.S.), Dechra Pharmaceuticals Plc (U.K.), Norbrook (U.K.), Chanelle Pharma (Ireland), Bimeda, Inc. (Ireland), Ceva Animal Health, LLC (U.S.), Inovet (Subsidiary of Orion Group Holdings Inc) (Hungary), and Durvet Animal Health Products (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global veterinary pain management market is segmented into eight notable segments on the basis of product type, drug type, mode of purchase, animal type, pain source, dosage, route of administration, and end user.
- On the basis of product type, the market is segmented into analgesics, corticosteroids, and alpha 2 agonists.
In 2023, the analgesics segment is expected to dominate the market
In 2023, the analgesics segment is expected to dominate the market with a 60.22% market share.
In 2023, the analgesics segment is expected to dominate the market due to rising prevalence of pet diseases and increasing approvals of the analgesics medications for veterinary pain management.
- On the basis of drug type, the market is segmented into branded and generic.
In 2023, the branded segment is expected to dominate the market
In 2023, the branded segment is expected to dominate the market with a 61.41% market share.
In 2023, the branded segment is expected to dominate the market due to the approvals of the drug medications for veterinary pain management.
- On the basis of mode of purchase, the market is segmented into prescription based and OTC. In 2023, the prescription based segment is expected to dominate the market with a 69.26% market share.
- On the basis of animal type, the market is segmented into companion animal and production animal. In 2023, the companion animal segment is expected to dominate the market with a 59.60% market share.
- On the basis of pain source, the market is segmented into chronic pain, acute pain, post-operative pain, and dental pain. In 2023, the chronic pain segment is expected to dominate the market with a 46.82% market share.
- On the basis of dosage, the market is segmented into solid, liquid, and semi-solid. In 2023, the solid segment is expected to dominate the market with a 46.62% market share
- On the basis of route of administration, the market is segmented into parenteral, oral, and topical. In 2023, the parenteral segment is expected to dominate the market with a 44.00% market share.
- On the basis of end user, the market is segmented into veterinary hospitals, veterinary clinics, pet shops, animal farms, academic & research institutes, and others. In 2023, the veterinary hospitals segment is expected to dominate the market with a 34.49% market share.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in the global veterinary pain management market that include Zoetis Services LLC (U.S.), Elanco (U.S.), Merck & Co., Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), and Vetoquinol (France) among others.
Market Developments
- In June 2023, Norbrook sponsored the International Society of Feline Medicine (ISFM) Congress in Dublin as a platinum sponsor. The International Society of Feline Medicine (ISFM) assists in providing veterinarians and nurses with the information they need to successfully treat cat health issues. Their annual Congress was held in Dublin, and Norbrook was well-represented there, with a strong emphasis on our main cat products, Thyronorm and Loxicom
- In May 2023, Zoetis Services LLC announced that the U.S. Food and Drug Administration (FDA) approved Librela (bedinvetmab injectable) for the treatment of osteoarthritis (OA) pain in dogs. Librela is the first and only anti-NGF monoclonal antibody medication for canine OA pain that is administered once a month. It is both safe and successful in giving dogs long-term relief from the symptoms of OA pain, which can enhance their mobility and general quality of life
- In May 2023, Virbac completed the purchase of all of the shares of its former distributor in the Czech Republic and Slovakia with the establishment of the 35th Virbac subsidiary. This acquisition is the result of years of hard effort by the teams led by Jakub Satrapa, the business's former owner and our future subsidiary's general manager. This is acknowledged by their inclusion in the Virbac clan. With the help of our new Virbac subsidiary, we will be able to more effectively and swiftly address the health needs of animals in Slovakia and the Czech Republic
- In March 2023, MSD Animal Health a division of Merck & Co., Inc. announced that it would organize a virtual continuing education symposium with 12 international experts as speakers. The event, which is being sponsored by NOBIVAC, will take place online on May 31, 2023, from 7 a.m. to 1 p.m. EDT, and it will include 11 talks spread across two parallel tracks (medical and business), addressing subjects including the future of vaccine innovation and enhancing the experience of getting a vaccine appointment. The occasion is without cost
Regional Analysis
Geographically, the countries covered in the global veterinary pain management market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Poland, Denmark, Sweden, Norway, Funland, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Taiwan, Vietnam, rest of Asia-Pacific, South Africa, Saudi Arabi, U.A.E., Egypt, Israel, Kuwait, Oman, Qatar, Bahrain, rest of the Middle East and Africa, Brazil, Argentina, and rest of South America.
As per Data Bridge Market Research analysis:
North America is the dominant and fastest-growing region in the market during the forecast period 2023-2030.
North America is expected to dominate and grow with the highest CAGR during the forecast period due to strong base of healthcare facilities, rise in the demand for efficient animal care, steady rise in the number of pet owners in this region and rising number of research activities in this region.
For more detailed information about the Global veterinary pain management market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-veterinary-pain-management-market
